Showing results (111-120 of 325) with videos related to
Sort By:
Pageof 33
Thrombosis Research|July 1, 1991
Components of coagulation and fibrinolysis during thrombosis prophylaxis with a low molecular weight heparin (Enoxaparin) versus Dextran 70 in hip arthroplastyL C Borris, J V Sørensen, M R Lassen, et al.Journal of Cardiac Surgery|January 28, 2005
Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularizationO Iqbal, M Tobu, S Aziz, et al.The Medical Clinics of North America|July 1, 1998
Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapyJ M Walenga, R L BickJournal of Thrombosis and Haemostasis : JTH|January 22, 2015
Complexes of platelet factor 4 and heparin activate Toll-like receptor 4M M Prechel, J M WalengaSeminars in Thrombosis and Hemostasis|January 1, 1996
Current trends in antithrombotic drug and device developmentJ FareedSeminars in Thrombosis and Hemostasis|January 1, 1985
Heparin, its fractions, fragments and derivatives. Some newer perspectivesJ FareedJournal Des Maladies Vasculaires|January 1, 1987
[Low molecular weight heparin fractions. Comparative preclinical study of various parameters]J FareedFolia Haematologica (Leipzig, Germany : 1928)|January 1, 1989
Recent development in antithrombotic therapyJ FareedJournal of Thrombosis and Thrombolysis|January 13, 2001
Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopeniaJ M Walenga, W P Jeske, H L MessmoreSeminars in Thrombosis and Hemostasis|June 5, 1999
Failure of current strategies in the prevention of thrombosis in patients with heparin-induced thrombocytopenia: a clinician's perspectiveD E Wallis, B E Lewis, J M WalengaPageof 33